PPT-Maternal immunization: Regulatory

and Ethical considerations in the EU Pieter Neels MD Independent Regulatory Expert Associate Professor University of Namur Advisory Board Member of NDA Ex CHMP member for Belgium Ex Vicechair VWP EMA. 7 2005 280 180430 73000 480 26196 92 2000 370 240560 97000 270 26697 121 1995 460 300720 123000 60 26689 155 1990 560 360870 148000 26632 192 Annual change 19902000 41 20002013 50 19902013 46 a World population prospects the 2012 revision New York P 2014. Summary presentation of key indicators. Updated . July 2015. Global Immunization 1980-2014, DTP3 coverage. global coverage at 86% in 2014. Source: WHO/UNICEF coverage estimates 2014 revision. July 2015. [INSERT NAMES OF PRESENTERS]. [INSERT YOUR PRACTICE’S NAME AND LOGO]. Last updated September 2017. HOW TO PREPARE FOR THIS PRESENTATION. Review your practice’s current immunization procedures. If they differ from the recommendations presented . WHO Technical Briefing Seminar on Essential Medicines and Health Products. 31 October 2013. WHO Headquarters, Geneva, Salle M 505. Dr Claudia P Alfonso . Outline. Global overview of vaccine production and immunization . Practical considerations for the successful introduction of Inactivated Polio Vaccine (IPV). 2. Contents. What are the WHO recommendations?. How to successfully introduce IPV. ?. How to effectively prepare healthcare workers for IPV introduction?. WHO Technical Briefing Seminar on Essential Medicines and Health Products. 31 October 2013. WHO Headquarters, Geneva, Salle M 505. Dr Claudia P Alfonso . Outline. Global overview of vaccine production and immunization . Practical considerations for the successful introduction of Inactivated Polio Vaccine (IPV). 2. Contents. What are the WHO recommendations?. How to successfully introduce IPV. ?. How to effectively prepare healthcare workers for IPV introduction?. Immunization Programs: State of the States on Adult Immunization Katelyn Wells PhD AIM Research and Development Directo r Objectives Status of Immunization Programs (IPs) promoting NVAC Adult Immunization ��Routine Immunization Products3.7Immunization with Influenza(Inf)Vaccine Background Influenza is a respiratory infection caused by either the type A or type B influenza viruses, and oc Immunization against infectious diseases is on of the greatest successes of modern medicine last 200 years of. Edward Jenner,. vaccination has controlled nine major diseases- smallpox, diphtheria, pertussis, tetanus, poliomyelitis, mumps, measles, rubella and yellow fever.. An overview of routine immunization services in developing countries. Presentation I Outline. Broad overview of Routine Immunization (RI). History of Expanded Program on Immunization (EPI). About the RI vaccines. Naima T. Joseph MD, MPH. Maternal-Fetal Medicine Specialist. Boston Medical Center. Brenna Hughes, MD, MSc. Maternal-Fetal Medicine Specialist. Duke Medicine. Introduction. Respiratory Syncytial Virus (RSV) is a leading cause of respiratory morbidity in infants. Immunization is an Efficient and Cost-Effective Investment. Note: this presentation draws heavily on materials from the WHO Euro Immunization Advocacy Library and . VoICE. , The Value of Immunization Compendium of Evidence. programmatic use considerations to protect infants in low- and middle-income countries. Last updated: June 2024. Access these and additional slides offered as part of an RSV communications toolkit at:.